Dr Reddy's semaglutide supply hit till late Oct

What happened and why it matters

Dr Reddy’s Laboratories said it will delay commercial supplies of certain batches of its generic semaglutide product after a quality-related issue linked to the active pharmaceutical ingredient (API). The development hit sentiment because semaglutide is a key ingredient used in blockbuster diabetes and obesity treatments globally. The company disclosed that certain batches of semaglutide were found to be “out of specification.” After the disclosure, Dr Reddy’s market capitalisation fell by about $178 million, according to Reuters. Investors also focused on the lack of clarity on the duration of disruption in the initial communication. Later reporting added more detail on timelines for availability in specific markets.

Company disclosure: out-of-spec API batches

In a statement to stock exchanges, Dr Reddy’s said certain batches of semaglutide API were found to be out of specification due to an issue associated with the API used in the product. The company said it is investigating the root cause and taking corrective measures to ensure product quality. It also stated that there is no impact on patient safety. Dr Reddy’s added there is no impact on the product’s existing global regulatory filings. The company said it has sufficient production capacity to meet demand, while it works through the issue.

Supply impact: India unavailable, Canada disrupted

Reuters reported that supplies of Dr Reddy’s generic semaglutide would remain unavailable in India and face disruptions in Canada until at least late October. The report said the issue with the API halted new production. Dr Reddy’s did not specify in its initial statement until when the supply disruption would last. The late-October timeline became important because it gives the market a clearer window of near-term sales disruption in two geographies. The company’s communication emphasised quality and remediation steps, but did not provide batch-level details or revised shipment schedules.

How markets reacted: sharp fall in the stock

The quality update triggered a steep single-day decline in the stock. Reuters said shares closed down 5.9% at ₹1,269.50, the steepest one-day fall in more than three years. Another report noted the stock tumbled 6.29% to ₹1,263.90 after the company said commercial supplies would be delayed. In subsequent trading referenced in the provided text, the stock opened at ₹1,220.20 against a previous close of ₹1,270.10 and rose to an intraday high of ₹1,303.55. Latest NSE data in the provided text showed the shares trading at ₹1,316, down ₹15 or 1.13%.

Why semaglutide is closely watched

Semaglutide is the key ingredient in widely used diabetes and obesity drugs, and it has become a major focus area for companies building complex generics and related portfolios. For Dr Reddy’s, broker commentary in the provided text links the investment case to semaglutide launches and approvals, alongside biosimilars. When an API issue interrupts production, it raises near-term execution risk even if the company states there is no patient safety impact. It can also pressure near-term expectations, especially when markets are already weighing base-business trends such as pricing pressure.

Brokerage actions: targets cut, ratings mostly cautious

Multiple brokerages adjusted targets or reiterated cautious views after the update and related developments. Motilal Oswal maintained a ‘Neutral’ rating and cut its target price to ₹1,195. Morgan Stanley retained an Equal-weight rating and cut its target to ₹1,215 from ₹1,259. Citi maintained a Sell call with a target of ₹1,070, while Jefferies maintained an Underperform rating with an unchanged target of ₹1,040. Goldman Sachs downgraded the stock to ‘Sell’ from Neutral and set a target price of ₹1,075.

Mixed takes: selective positives alongside near-term caution

Some broker notes in the provided text still point to longer-term opportunities from semaglutide and biosimilars, even as they trim estimates. ICICI Securities maintained an “add” view while reducing the target to ₹1,365 from ₹1,435, and cut FY27-28E EPS estimates by nearly 5% to factor in lower margins for the base business. Equirus Securities reiterated a “short” view with a target of ₹1,091, citing expectations of downward revisions to Street estimates given muted base business performance. Another note referenced in the provided text said, “We cut the TP from ₹1,600 to ₹1,550; retain ‘BUY’,” while a separate view raised its target multiple by 10% and set a revised target price at ₹1,335 with an ADD rating. Systematix Shares and Stocks (India) upgraded Dr Reddy’s to ‘buy’ with a target price of ₹1,381, while also lowering its P/E multiple to 21 times FY28 earnings from 25 times FY28.

Technical levels flagged by market watchers

The provided text also included technical levels cited by an expert. Fresh buying interest was seen as more likely only if the stock closes decisively above ₹1,305 on a daily basis. Support was seen around ₹1,230, with a breach potentially leading to further selling pressure towards ₹1,200. These are market observations included in the supplied material and reflect trading levels, not company guidance.

Key facts at a glance

What investors may watch next

The next key update will be any further disclosure on the root cause, corrective measures, and the timing of resumed commercial supplies. Market attention is likely to remain on how long the disruption persists in India and Canada, given the late-October reference in the Reuters report. Brokerages have already adjusted targets and, in some cases, earnings estimates based on margin and execution assumptions stated in their notes. Separately, commentary in the provided text links the broader story to timely commercialisation of semaglutide in Canada and Brazil and to biosimilar abatacept commercialisation globally. Any confirmed milestones on these fronts, along with clarity on supply normalisation, are likely to shape the next phase of investor expectations.